Charles River Laboratories International, Inc. (CRL): Price and Financial Metrics

Charles River Laboratories International, Inc. (CRL)

Today's Latest Price: $280.18 USD

1.06 (-0.38%)

Updated Jan 22 7:00pm

Add CRL to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 64 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

CRL Stock Summary

  • CRL has a higher market value than 85.6% of US stocks; more precisely, its current market capitalization is $13,989,616,136.
  • With a one year PEG ratio of 177.64, Charles River Laboratories International Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 81.81% of US stocks.
  • The price/operating cash flow metric for Charles River Laboratories International Inc is higher than 77.9% of stocks in our set with a positive cash flow.
  • Stocks that are quantitatively similar to CRL, based on their financial statements, market capitalization, and price volatility, are PRAH, BR, TTEK, RXN, and FOXA.
  • Visit CRL's SEC page to see the company's official filings. To visit the company's web site, go to

CRL Stock Price Chart Interactive Chart >

Price chart for CRL

CRL Price/Volume Stats

Current price $280.18 52-week high $284.60
Prev. close $281.24 52-week low $95.58
Day low $277.36 Volume 169,500
Day high $282.09 Avg. volume 325,221
50-day MA $247.80 Dividend yield N/A
200-day MA $208.60 Market Cap 13.94B

Charles River Laboratories International, Inc. (CRL) Company Bio

Charles River Laboratories provides products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. The company was founded in 1947 and is based in Wilmington, Massachusetts.

CRL Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$280.18$154.79 -45%

We started the process of determining a valid price forecast for Charles River Laboratories International Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Charles River Laboratories International Inc ranked in the 37th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Charles River Laboratories International Inc, consider:

  • 87% of the company's capital comes from equity, which is greater than 66.47% of stocks in our cash flow based forecasting set.
  • The weighted average cost of capital for the company is 9. This value is greater than just 23.35% stocks in the Healthcare sector that generate free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of Charles River Laboratories International Inc? See MMSI, MGLN, PKI, ITGR, and IART.

CRL Latest News Stream

Event/Time News Detail
Loading, please wait...

CRL Latest Social Stream

Loading social stream, please wait...

View Full CRL Social Stream

Latest CRL News From Around the Web

Below are the latest news stories about Charles River Laboratories International Inc that investors may wish to consider to help them evaluate CRL as an investment opportunity.

Charles River Laboratories Schedules Fourth-Quarter 2020 Earnings and 2021 Guidance Release and Conference Call

Charles River Laboratories schedules fourth-quarter 2020 earnings and 2021 guidance release and conference call.

Yahoo | January 20, 2021

Charles River Laboratories International (CRL) Presents At 39th Annual JP Morgan Healthcare Conference - Slideshow

The following slide deck was published by Charles River Laboratories International, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | January 19, 2021

Ariel Investments, Still Hopeful for Charles River Lab (CRL) to Continue Positive Momentum

Ariel Investments, a minority-owned investment company that focuses in small and mid-capitalized US based stocks, published its third-quarter 2020 Investor Letter – a copy of which can be downloaded here. A positive return of 4.56% was recorded by the fund for the 3rd Quarter of 2020, ahead of its Russell 2500 Value benchmark that returned 3.54%. […]

Yahoo | January 15, 2021

Charles River Laboratories to Present at J.P. Morgan Healthcare Conference

Charles River Laboratories to present at J.P. Morgan Healthcare Conference

Yahoo | January 11, 2021

Charles River Labs Eyes 'SuperHuman' Gains As Breakout Nears

While Tesla and NVDA stock have soared in recent years, Charles River Labs has made a 'SuperHuman' run of its own as CRL stock nears another breakout.

Yahoo | January 6, 2021

Read More 'CRL' Stories Here

CRL Price Returns

1-mo 11.31%
3-mo 20.35%
6-mo 40.14%
1-year 80.41%
3-year 165.50%
5-year 269.92%
YTD 12.13%
2020 63.56%
2019 34.97%
2018 3.41%
2017 43.65%
2016 -5.22%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7545 seconds.